Export

EN
FR
Efavirenz + lamivudine + tenofovir
Essential medicine status
General description
A fixed-dose combination of two nucleoside reverse-transcriptase inhibitors (NRTIs, lamivudine and tenofovir disoproxil fumarate) and a non-nucleoside reverse transcriptase inhibitor (NNRTI, efavirenz) for treatment of human immunodeficiency virus (HIV) disease.
INN
Efavirenz + lamivudine + tenofovir
ATC codes
J05AR11
Medicine type
Chemical agent
EML status history
Therapeutic equivalent for
efavirenz + emtricitabine + tenofovir for Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
Wikipedia
Efavirenz + lamivudine + tenofovir
DrugBank
Efavirenz ,
Lamivudine ,
Tenofovir disoproxil
Recommendations
Section
Fixed-dose combinations of antiretrovirals
  • Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)
Indications
Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified